Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
NCT06345495Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), splenomegaly, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)splenomegaly
Beyond the preview
Go deeper on NCT06345495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345495.